Baader Wertpapierhandelsbank announced Bayer (ETR:BAYN), raising its target price to 81.00EUR today
- Updated: September 29, 2016
Yesterday Bayer (ETR:BAYN) traded 0.00% even at 88.31EUR. The company’s 50-day moving average is 0.04EUR and its 200-day moving average is 0.03EUR. The last closing price is up -4.07% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 0 shares of Bayer traded, down from an avg. volume of 215
Bayer (ETR:BAYN) had its target price raised to 81.00EUR by Baader Wertpapierhandelsbank in a report released Thursday September 29, 2016. The new target price indicates a possible downside of -0.08% based on the company's last closing price.
Previously on 09/28/2016, Bankhaus Lampe KG reported on Bayer (ETR:BAYN) raised the target price from 0.00EUR to 103.00EUR. At the time, this indicated a possible upside of 0.16%.
With a total market value of 0 EUR, Bayer has with a one year low of 0.03EUR and a one year high of 0.04EUR .
More About Bayer (ETR:BAYN)
Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, adhesives and sealants; and selected chemical intermediates.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.